<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03781830</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00177456</org_study_id>
    <nct_id>NCT03781830</nct_id>
  </id_info>
  <brief_title>mDOT for Immunosuppressant Adherence in Adolescent Liver Transplant Recipients</brief_title>
  <official_title>A Pilot Study of Mobile Directly Observed Therapy (mDOT) for Immunosuppressant Adherence in Adolescent Liver Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are interested in whether or not the use of a mobile health (mHealth)&#xD;
      application increases the rate of immunosuppression medication adherence among adolescent&#xD;
      liver transplant recipients. The investigators aim to test this by recruiting adolescent&#xD;
      (ages 14-21) liver transplant recipients to use an mHealth application to record themselves&#xD;
      taking their immunosuppression medications, and tracking medication adherence over time. The&#xD;
      study population will be approximately 25 adolescent liver transplant recipients at the Johns&#xD;
      Hopkins Hospital.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-adherence to immunosuppressive medications among organ transplant recipients is&#xD;
      associated with a range of short- and long-term complications, and non-adherence is almost 4&#xD;
      times higher in pediatric and adolescent patients compared to adult transplant recipients.&#xD;
      Previous studies have reported rates of non-adherence in this population ranging from 50-70%.&#xD;
      Medication non-adherence in adolescents is associated with increased disease frustration,&#xD;
      poor regimen adaptation/cognitive issues, difficulty with ingestion (e.g., number of&#xD;
      medications, taste), and lack of parental monitoring and involvement. Among pediatric&#xD;
      transplant recipients, psychosocial variables (e.g., psychiatric co-morbidities; child&#xD;
      responsibility for medication) are strong determinants of nonadherence. Medication adherence&#xD;
      is a key concern in the transition from pediatric to adult-centered transplant care, and&#xD;
      transition planning should be prioritized in these transplant patients. Therefore, the&#xD;
      investigators believe that the use of mobile health (mHealth) technology has the potential to&#xD;
      allow clinicians and researchers to better understand nonadherence in pediatric transplant&#xD;
      recipients, and increase immunosuppressive medication adherence.&#xD;
&#xD;
      The investigators will use a mobile health platform that enables users to track dose-by-dose&#xD;
      medication adherence through asynchronous, video directly observed therapy (DOT). This helps&#xD;
      patients take their medication as prescribed and gives providers the assurance that their&#xD;
      patients are supported and successful in treatment. DOT is the practice of watching a patient&#xD;
      take every dose of medicine in-person, and has typically only been done in extreme cases&#xD;
      because it can be both costly and burdensome: DOT is the standard of care for Tuberculosis&#xD;
      treatment and has proven high-adherence rates. Through mHealth technology, DOT can be used&#xD;
      more broadly and without added burden; emocha's technology allows this through enabling&#xD;
      patients to use their mobile application to view their regimen, record themselves taking&#xD;
      every dose of their medication, report side effects or symptoms, visualize their treatment&#xD;
      progress, and access educational content. This information is encrypted and transmitted to a&#xD;
      HIPAA-secure web portal for providers to review. The aim of this study is to understand&#xD;
      medication adherence in adolescent liver transplant recipients using the mHealth application.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Recruiting under the new mDOT clinical trial with PI D Mogul&#xD;
  </why_stopped>
  <start_date type="Actual">June 18, 2020</start_date>
  <completion_date type="Actual">November 12, 2020</completion_date>
  <primary_completion_date type="Actual">November 12, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a single center prospective trial. Participants in this study will use the mHealth application to manage and track their immunosuppression medical regimen post-transplant.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-week immunosuppression adherence</measure>
    <time_frame>12 weeks</time_frame>
    <description>After 12 weeks in the study, patients will complete the 4-item immunosuppressant therapy adherence instrument (ITAS) to determine self-reported medication adherence (scores range from 0-12 with 0 indicating very poor adherence and 12 indicating perfect adherence). Additionally, immunosuppression level trends will be tracked via electronic medical record review to determine medication adherence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility of using the mHealth Application as Assessed by a Semi-Structured Interview and a 17-Item Survey</measure>
    <time_frame>12 weeks</time_frame>
    <description>After 12 weeks in the study, participants will be asked to participate in a semi-structured phone interview in which they will answer questions regarding their medication adherence habits and their thoughts on how our mHealth technology was or was not helpful. They will also complete a 17-question post-satisfaction survey assessing their satisfaction levels with the mhealth technology. Responses in the 17-item survey are on a 7-item Likert scale, ranging from Strongly Agree to Strongly Disagree.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Medication Adherence</condition>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>mHealth Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the mHealth application either while they are an inpatient post-transplant, or at one of their post-transplant clinic visits. Study personnel will assist participants with downloading the mHealth application and explain its functioning. Participants will then use the application to aid in immunosuppressive medication adherence post-transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mHealth Intervention</intervention_name>
    <description>The video DOT app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.</description>
    <arm_group_label>mHealth Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adolescents (14-21 years old)&#xD;
&#xD;
          -  Have received a liver transplant at the Johns Hopkins Hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-English speaking&#xD;
&#xD;
          -  International&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Macey Henderson, JD, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>De Geest S, Borgermans L, Gemoets H, Abraham I, Vlaminck H, Evers G, Vanrenterghem Y. Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients. Transplantation. 1995 Feb 15;59(3):340-7.</citation>
    <PMID>7871562</PMID>
  </reference>
  <reference>
    <citation>Butler JA, Roderick P, Mullee M, Mason JC, Peveler RC. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation. 2004 Mar 15;77(5):769-76. doi: 10.1097/01.tp.0000110408.83054.88.</citation>
    <PMID>15021846</PMID>
  </reference>
  <reference>
    <citation>Foster BJ, Dahhou M, Zhang X, Platt RW, Samuel SM, Hanley JA. Association between age and graft failure rates in young kidney transplant recipients. Transplantation. 2011 Dec 15;92(11):1237-43. doi: 10.1097/TP.0b013e31823411d7.</citation>
    <PMID>22124283</PMID>
  </reference>
  <reference>
    <citation>Douglas S, Blixen C, Bartucci MR. Relationship between pretransplant noncompliance and posttransplant outcomes in renal transplant recipients. J Transpl Coord. 1996 Jun;6(2):53-8. doi: 10.7182/prtr.1.6.2.x11r325882657x21.</citation>
    <PMID>9188358</PMID>
  </reference>
  <reference>
    <citation>Burra P, Germani G, Gnoato F, Lazzaro S, Russo FP, Cillo U, Senzolo M. Adherence in liver transplant recipients. Liver Transpl. 2011 Jul;17(7):760-70. doi: 10.1002/lt.22294.</citation>
    <PMID>21384527</PMID>
  </reference>
  <reference>
    <citation>Mehta P, Steinberg EA, Kelly SL, Buchanan C, Rawlinson AR. Medication adherence among adolescent solid-organ transplant recipients: A survey of healthcare providers. Pediatr Transplant. 2017 Nov;21(7). doi: 10.1111/petr.13018. Epub 2017 Jul 2.</citation>
    <PMID>28670855</PMID>
  </reference>
  <reference>
    <citation>Dobbels F, Van Damme-Lombaert R, Vanhaecke J, De Geest S. Growing pains: non-adherence with the immunosuppressive regimen in adolescent transplant recipients. Pediatr Transplant. 2005 Jun;9(3):381-90. doi: 10.1111/j.1399-3046.2005.00356.x.</citation>
    <PMID>15910397</PMID>
  </reference>
  <reference>
    <citation>Fredericks EM, Lopez MJ, Magee JC, Shieck V, Opipari-Arrigan L. Psychological functioning, nonadherence and health outcomes after pediatric liver transplantation. Am J Transplant. 2007 Aug;7(8):1974-83. doi: 10.1111/j.1600-6143.2007.01878.x.</citation>
    <PMID>17617862</PMID>
  </reference>
  <reference>
    <citation>Pai AL, McGrady M. Systematic review and meta-analysis of psychological interventions to promote treatment adherence in children, adolescents, and young adults with chronic illness. J Pediatr Psychol. 2014 Sep;39(8):918-31. doi: 10.1093/jpepsy/jsu038. Epub 2014 Jun 20.</citation>
    <PMID>24952359</PMID>
  </reference>
  <reference>
    <citation>Shaw RJ, Palmer L, Blasey C, Sarwal M. A typology of non-adherence in pediatric renal transplant recipients. Pediatr Transplant. 2003 Dec;7(6):489-93. doi: 10.1046/j.1397-3142.2003.00117.x.</citation>
    <PMID>14870900</PMID>
  </reference>
  <reference>
    <citation>Simons LE, Blount RL. Identifying barriers to medication adherence in adolescent transplant recipients. J Pediatr Psychol. 2007 Aug;32(7):831-44. doi: 10.1093/jpepsy/jsm030. Epub 2007 May 23.</citation>
    <PMID>17522111</PMID>
  </reference>
  <reference>
    <citation>Simons LE, McCormick ML, Devine K, Blount RL. Medication barriers predict adolescent transplant recipients' adherence and clinical outcomes at 18-month follow-up. J Pediatr Psychol. 2010 Oct;35(9):1038-48. doi: 10.1093/jpepsy/jsq025. Epub 2010 Apr 20.</citation>
    <PMID>20410021</PMID>
  </reference>
  <reference>
    <citation>Kahana SY, Frazier TW, Drotar D. Preliminary quantitative investigation of predictors of treatment non-adherence in pediatric transplantation: a brief report. Pediatr Transplant. 2008 Sep;12(6):656-60. doi: 10.1111/j.1399-3046.2007.00864.x.</citation>
    <PMID>18798360</PMID>
  </reference>
  <reference>
    <citation>Berquist RK, Berquist WE, Esquivel CO, Cox KL, Wayman KI, Litt IF. Adolescent non-adherence: prevalence and consequences in liver transplant recipients. Pediatr Transplant. 2006 May;10(3):304-10. doi: 10.1111/j.1399-3046.2005.00451.x.</citation>
    <PMID>16677353</PMID>
  </reference>
  <reference>
    <citation>Watson AR. Non-compliance and transfer from paediatric to adult transplant unit. Pediatr Nephrol. 2000 Jun;14(6):469-72. doi: 10.1007/s004670050794.</citation>
    <PMID>10872185</PMID>
  </reference>
  <reference>
    <citation>Dobbels F, Ruppar T, De Geest S, Decorte A, Van Damme-Lombaerts R, Fine RN. Adherence to the immunosuppressive regimen in pediatric kidney transplant recipients: a systematic review. Pediatr Transplant. 2010 Aug;14(5):603-13. doi: 10.1111/j.1399-3046.2010.01299.x. Epub 2010 Feb 28.</citation>
    <PMID>20214741</PMID>
  </reference>
  <reference>
    <citation>Annunziato RA, Emre S, Shneider B, Barton C, Dugan CA, Shemesh E. Adherence and medical outcomes in pediatric liver transplant recipients who transition to adult services. Pediatr Transplant. 2007 Sep;11(6):608-14. doi: 10.1111/j.1399-3046.2007.00689.x.</citation>
    <PMID>17663682</PMID>
  </reference>
  <reference>
    <citation>Fredericks EM, Dore-Stites D, Well A, Magee JC, Freed GL, Shieck V, James Lopez M. Assessment of transition readiness skills and adherence in pediatric liver transplant recipients. Pediatr Transplant. 2010 Dec;14(8):944-53. doi: 10.1111/j.1399-3046.2010.01349.x.</citation>
    <PMID>20598086</PMID>
  </reference>
  <reference>
    <citation>Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016 Oct 1;63(7):e147-e195. doi: 10.1093/cid/ciw376. Epub 2016 Aug 10.</citation>
    <PMID>27516382</PMID>
  </reference>
  <reference>
    <citation>Chisholm MA, Lance CE, Williamson GM, Mulloy LL. Development and validation of the immunosuppressant therapy adherence instrument (ITAS). Patient Educ Couns. 2005 Oct;59(1):13-20. doi: 10.1016/j.pec.2004.09.003.</citation>
    <PMID>16198214</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 7, 2018</study_first_submitted>
  <study_first_submitted_qc>December 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2018</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mHealth</keyword>
  <keyword>liver transplantation</keyword>
  <keyword>medication adherence</keyword>
  <keyword>video directly observed therapy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03781830
org study id: IRB00177456
nct id: NCT03781830
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
The investigators are interested in whether or not the use of a mobile health (mHealth)
      application increases the rate of immunosuppression medication adherence among adolescent
      liver transplant recipients. The investigators aim to test this by recruiting adolescent
      (ages 14-21) liver transplant recipients to use an mHealth application to record themselves
      taking their immunosuppression medications, and tracking medication adherence over time. The
      study population will be approximately 25 adolescent liver transplant recipients at the Johns
      Hopkins Hospital.
Non-adherence to immunosuppressive medications among organ transplant recipients is
      associated with a range of short- and long-term complications, and non-adherence is almost 4
      times higher in pediatric and adolescent patients compared to adult transplant recipients.
      Previous studies have reported rates of non-adherence in this population ranging from 50-70%.
      Medication non-adherence in adolescents is associated with increased disease frustration,
      poor regimen adaptation/cognitive issues, difficulty with ingestion (e.g., number of
      medications, taste), and lack of parental monitoring and involvement. Among pediatric
      transplant recipients, psychosocial variables (e.g., psychiatric co-morbidities; child
      responsibility for medication) are strong determinants of nonadherence. Medication adherence
      is a key concern in the transition from pediatric to adult-centered transplant care, and
      transition planning should be prioritized in these transplant patients. Therefore, the
      investigators believe that the use of mobile health (mHealth) technology has the potential to
      allow clinicians and researchers to better understand nonadherence in pediatric transplant
      recipients, and increase immunosuppressive medication adherence.

      The investigators will use a mobile health platform that enables users to track dose-by-dose
      medication adherence through asynchronous, video directly observed therapy (DOT). This helps
      patients take their medication as prescribed and gives providers the assurance that their
      patients are supported and successful in treatment. DOT is the practice of watching a patient
      take every dose of medicine in-person, and has typically only been done in extreme cases
      because it can be both costly and burdensome: DOT is the standard of care for Tuberculosis
      treatment and has proven high-adherence rates. Through mHealth technology, DOT can be used
      more broadly and without added burden; emocha's technology allows this through enabling
      patients to use their mobile application to view their regimen, record themselves taking
      every dose of their medication, report side effects or symptoms, visualize their treatment
      progress, and access educational content. This information is encrypted and transmitted to a
      HIPAA-secure web portal for providers to review. The aim of this study is to understand
      medication adherence in adolescent liver transplant recipients using the mHealth application.
allocation: N/A
intervention model: Single Group Assignment
intervention model description: This is a single center prospective trial. Participants in this study will use the mHealth application to manage and track their immunosuppression medical regimen post-transplant.
primary purpose: Supportive Care
masking: None (Open Label)
measure: 12-week immunosuppression adherence
time frame: 12 weeks
description: After 12 weeks in the study, patients will complete the 4-item immunosuppressant therapy adherence instrument (ITAS) to determine self-reported medication adherence (scores range from 0-12 with 0 indicating very poor adherence and 12 indicating perfect adherence). Additionally, immunosuppression level trends will be tracked via electronic medical record review to determine medication adherence.
measure: Feasibility of using the mHealth Application as Assessed by a Semi-Structured Interview and a 17-Item Survey
time frame: 12 weeks
description: After 12 weeks in the study, participants will be asked to participate in a semi-structured phone interview in which they will answer questions regarding their medication adherence habits and their thoughts on how our mHealth technology was or was not helpful. They will also complete a 17-question post-satisfaction survey assessing their satisfaction levels with the mhealth technology. Responses in the 17-item survey are on a 7-item Likert scale, ranging from Strongly Agree to Strongly Disagree.
arm group label: mHealth Intervention
arm group type: Experimental
description: Participants will receive the mHealth application either while they are an inpatient post-transplant, or at one of their post-transplant clinic visits. Study personnel will assist participants with downloading the mHealth application and explain its functioning. Participants will then use the application to aid in immunosuppressive medication adherence post-transplant.
intervention type: Other
intervention name: mHealth Intervention
description: The video DOT app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
arm group label: mHealth Intervention
criteria: 
gender: All
minimum age: 14 Years
maximum age: 21 Years
healthy volunteers: No
last name: Macey Henderson, JD, Phd
role: Principal Investigator
affiliation: Johns Hopkins University
facility: 
country: United States
citation: De Geest S, Borgermans L, Gemoets H, Abraham I, Vlaminck H, Evers G, Vanrenterghem Y. Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients. Transplantation. 1995 Feb 15;59(3):340-7.
PMID: 7871562
citation: Butler JA, Roderick P, Mullee M, Mason JC, Peveler RC. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation. 2004 Mar 15;77(5):769-76. doi: 10.1097/01.tp.0000110408.83054.88.
PMID: 15021846
citation: Foster BJ, Dahhou M, Zhang X, Platt RW, Samuel SM, Hanley JA. Association between age and graft failure rates in young kidney transplant recipients. Transplantation. 2011 Dec 15;92(11):1237-43. doi: 10.1097/TP.0b013e31823411d7.
PMID: 22124283
citation: Douglas S, Blixen C, Bartucci MR. Relationship between pretransplant noncompliance and posttransplant outcomes in renal transplant recipients. J Transpl Coord. 1996 Jun;6(2):53-8. doi: 10.7182/prtr.1.6.2.x11r325882657x21.
PMID: 9188358
citation: Burra P, Germani G, Gnoato F, Lazzaro S, Russo FP, Cillo U, Senzolo M. Adherence in liver transplant recipients. Liver Transpl. 2011 Jul;17(7):760-70. doi: 10.1002/lt.22294.
PMID: 21384527
citation: Mehta P, Steinberg EA, Kelly SL, Buchanan C, Rawlinson AR. Medication adherence among adolescent solid-organ transplant recipients: A survey of healthcare providers. Pediatr Transplant. 2017 Nov;21(7). doi: 10.1111/petr.13018. Epub 2017 Jul 2.
PMID: 28670855
citation: Dobbels F, Van Damme-Lombaert R, Vanhaecke J, De Geest S. Growing pains: non-adherence with the immunosuppressive regimen in adolescent transplant recipients. Pediatr Transplant. 2005 Jun;9(3):381-90. doi: 10.1111/j.1399-3046.2005.00356.x.
PMID: 15910397
citation: Fredericks EM, Lopez MJ, Magee JC, Shieck V, Opipari-Arrigan L. Psychological functioning, nonadherence and health outcomes after pediatric liver transplantation. Am J Transplant. 2007 Aug;7(8):1974-83. doi: 10.1111/j.1600-6143.2007.01878.x.
PMID: 17617862
citation: Pai AL, McGrady M. Systematic review and meta-analysis of psychological interventions to promote treatment adherence in children, adolescents, and young adults with chronic illness. J Pediatr Psychol. 2014 Sep;39(8):918-31. doi: 10.1093/jpepsy/jsu038. Epub 2014 Jun 20.
PMID: 24952359
citation: Shaw RJ, Palmer L, Blasey C, Sarwal M. A typology of non-adherence in pediatric renal transplant recipients. Pediatr Transplant. 2003 Dec;7(6):489-93. doi: 10.1046/j.1397-3142.2003.00117.x.
PMID: 14870900
citation: Simons LE, Blount RL. Identifying barriers to medication adherence in adolescent transplant recipients. J Pediatr Psychol. 2007 Aug;32(7):831-44. doi: 10.1093/jpepsy/jsm030. Epub 2007 May 23.
PMID: 17522111
citation: Simons LE, McCormick ML, Devine K, Blount RL. Medication barriers predict adolescent transplant recipients' adherence and clinical outcomes at 18-month follow-up. J Pediatr Psychol. 2010 Oct;35(9):1038-48. doi: 10.1093/jpepsy/jsq025. Epub 2010 Apr 20.
PMID: 20410021
citation: Kahana SY, Frazier TW, Drotar D. Preliminary quantitative investigation of predictors of treatment non-adherence in pediatric transplantation: a brief report. Pediatr Transplant. 2008 Sep;12(6):656-60. doi: 10.1111/j.1399-3046.2007.00864.x.
PMID: 18798360
citation: Berquist RK, Berquist WE, Esquivel CO, Cox KL, Wayman KI, Litt IF. Adolescent non-adherence: prevalence and consequences in liver transplant recipients. Pediatr Transplant. 2006 May;10(3):304-10. doi: 10.1111/j.1399-3046.2005.00451.x.
PMID: 16677353
citation: Watson AR. Non-compliance and transfer from paediatric to adult transplant unit. Pediatr Nephrol. 2000 Jun;14(6):469-72. doi: 10.1007/s004670050794.
PMID: 10872185
citation: Dobbels F, Ruppar T, De Geest S, Decorte A, Van Damme-Lombaerts R, Fine RN. Adherence to the immunosuppressive regimen in pediatric kidney transplant recipients: a systematic review. Pediatr Transplant. 2010 Aug;14(5):603-13. doi: 10.1111/j.1399-3046.2010.01299.x. Epub 2010 Feb 28.
PMID: 20214741
citation: Annunziato RA, Emre S, Shneider B, Barton C, Dugan CA, Shemesh E. Adherence and medical outcomes in pediatric liver transplant recipients who transition to adult services. Pediatr Transplant. 2007 Sep;11(6):608-14. doi: 10.1111/j.1399-3046.2007.00689.x.
PMID: 17663682
citation: Fredericks EM, Dore-Stites D, Well A, Magee JC, Freed GL, Shieck V, James Lopez M. Assessment of transition readiness skills and adherence in pediatric liver transplant recipients. Pediatr Transplant. 2010 Dec;14(8):944-53. doi: 10.1111/j.1399-3046.2010.01349.x.
PMID: 20598086
citation: Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016 Oct 1;63(7):e147-e195. doi: 10.1093/cid/ciw376. Epub 2016 Aug 10.
PMID: 27516382
citation: Chisholm MA, Lance CE, Williamson GM, Mulloy LL. Development and validation of the immunosuppressant therapy adherence instrument (ITAS). Patient Educ Couns. 2005 Oct;59(1):13-20. doi: 10.1016/j.pec.2004.09.003.
PMID: 16198214
responsible party type: Sponsor
sharing ipd: No